Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Mar;32(2):131–136. doi: 10.1007/BF01754210

Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies

C Bethan Powell 1, David G Mutch 1, L Stewart Massad 1, Ming-Shian Kao 1, John Leslie Collins 1,✉
PMCID: PMC11038370  PMID: 2289205

Abstract

The efficacy of tumor necrosis factor α (TNFα) as an anticancer agent is limited. This limitation might be related to the expression of a protein-synthesis-dependent resistance mechanism that prevents the lysis of tumor cells by TNFα. To test this possibility eight randomly selected human cell lines, three derived from ovarian carcinomas and five derived from cervical carcinomas, were tested for their in vitro sensitivity to TNFα-mediated lysis. The results of this analysis showed that all eight cell lines are normally resistant to lysis by TNFα. However, in the presence of inhibitors of protein synthesis, seven of them showed a significant increase in TNFα-mediated lysis. Measurement of protein synthesis showed that there is a linear correlation between the level of inhibition of protein synthesis and the level of TNFα-mediated lysis. The fact that seven of eight randomly selected cell lines are resistant to TNFα because they express a protein-synthesis-dependent resistance mechanism suggests that this mechanism of resistance may be common among gynecological cancers. The results also suggest that a therapy involving TNFα and inhibitors of protein synthesis might be useful for the treatment of gynecological malignancies.

Keywords: Carcinoma, Tumor Cell, Cancer Research, Protein Synthesis, Tumor Necrosis

References

  • 1.Aggarawal BB, Moffat B, Harkins RN. Human lymphotoxin. J Biol Chem. 1984;259:686. [PubMed] [Google Scholar]
  • 2.Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986. [PubMed] [Google Scholar]
  • 3.Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Collins JL, Patek PQ, Cohn M. Tumorigenicity and lysis by natural killers. J Exp Med. 1981;153:89. doi: 10.1084/jem.153.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Collins JL, Kao M-S, Patek PQ. Humans express natural cytotoxic (NC) cell activity that is similar to murine NC cell activity. J Immunol. 1987;138:4180. [PubMed] [Google Scholar]
  • 6.Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, Proefrock G. Phase I clinical trial recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:137. doi: 10.1007/BF00253968. [DOI] [PubMed] [Google Scholar]
  • 7.Darzynkiewicz Z, Carter SP, Old LJ. Effects of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D. J Cell Physiol. 1986;130:328. doi: 10.1002/jcp.1041300304. [DOI] [PubMed] [Google Scholar]
  • 8.De Filippi P, Poupart P, Tavernier J, Fiers W, Content J. Induction and regulation of m-RNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor. Proc Natl Acad Sci USA. 1987;84:4557. doi: 10.1073/pnas.84.13.4557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: Its effects and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol. 1986;22:419. doi: 10.1016/0277-5379(86)90107-0. [DOI] [PubMed] [Google Scholar]
  • 10.Friedman PA, Cerami A. Cancer medicine. Philadelphia: Lea and Febiger; 1973. Actinomycin; p. 835. [Google Scholar]
  • 11.Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med. 1981;51:191. [PubMed] [Google Scholar]
  • 12.Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki M, Wakui A, Yamada K. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:223. doi: 10.1007/BF00570490. [DOI] [PubMed] [Google Scholar]
  • 13.Kirstein M, Baglioni C. Tumor necrosis factor induces synthesis of two proteins in human fibroblasts. J Biol Chem. 1986;261:9565. [PubMed] [Google Scholar]
  • 14.Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol. 1988;141:2629. [PubMed] [Google Scholar]
  • 15.Ortaldo JR, Mason LH, Herberman RB. Relationship of mouse natural killer cells and mouse natural cytotoxic cells: effector cells and possible mechanism of action. Immunol Res. 1986;5:25. doi: 10.1007/BF02917191. [DOI] [PubMed] [Google Scholar]
  • 16.Ortaldo JR, Mason LH, Mathieson BJ, Liang S-M, Flick DA, Herberman RB. Mediation of mouse natural cytotoxic activity by tumor necrosis factor. Nature. 1986;321:700. doi: 10.1038/321700a0. [DOI] [PubMed] [Google Scholar]
  • 17.Patek PQ, Lin Y, Collins JL. Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms. J Immunol. 1987;138:1641. [PubMed] [Google Scholar]
  • 18.Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol. 1987;138:2711. [PubMed] [Google Scholar]
  • 19.Scanlon M, Laster SM, Wood JG, Gooding LR. Cytolysis by tumor necrosis factor is preceded by a rapid and specific dissolution of microfilaments. Proc Natl Acad Sci USA. 1989;86:182. doi: 10.1073/pnas.86.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344. doi: 10.1200/JCO.1988.6.2.344. [DOI] [PubMed] [Google Scholar]
  • 21.Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace B. Cloning and expression inEscherichia coli of the gene for human tumor necrosis factor. Nature. 1985;313:803. doi: 10.1038/313803a0. [DOI] [PubMed] [Google Scholar]
  • 22.Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  • 23.Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science. 1985;228:149. doi: 10.1126/science.3856324. [DOI] [PubMed] [Google Scholar]
  • 24.Wong GHW, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 1988;242:941. doi: 10.1126/science.3263703. [DOI] [PubMed] [Google Scholar]
  • 25.Wong GHW, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 1989;58:923. doi: 10.1016/0092-8674(89)90944-6. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES